Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Dissecting the First EU JCA
The first EU Joint Clinical Assessment (JCA) has moved from theory to reality, offering important lessons for pricing, market access, and evidence-generation teams. Using the tovorafenib assessment as a practical case study, this webinar will explore what the first JCA report reveals about evidence readiness, PICO alignment and uncertainty management under the new EU HTA framework.
Hosted by Paul Craddy, Charlie Hewitt & Lauren Boland
